Page last updated: 2024-08-24

capecitabine and Atypical Ductal Hyperplasia

capecitabine has been researched along with Atypical Ductal Hyperplasia in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ezaki, T; Iguchi, T; Ito, S; Koga, T; Nozoe, E; Nozoe, T; Ohga, T1
Clemens, MR; Darb-Esfahani, S; Denkert, C; Diebold, K; Dietrich, K; Eidtmann, H; Hanusch, C; Henschen, S; Hoffmann, G; Holms, F; Huober, J; Just, M; Loibl, S; Schrader, I; Solbach, C; Tesch, H; Tiemann, K; Untch, M; von Minckwitz, G1
Booser, DJ; Brewster, AM; Broglio, K; Buzdar, AU; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Hunt, KK; Ibrahim, NK; Kelly, CM; Thomas, ES; Valero, V; Walters, RS1

Trials

1 trial(s) available for capecitabine and Atypical Ductal Hyperplasia

ArticleYear
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Mar-20, Volume: 30, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome

2012

Other Studies

2 other study(ies) available for capecitabine and Atypical Ductal Hyperplasia

ArticleYear
[Combined therapy of lapatinib and capecitabine effective against local recurrence of breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Intraductal, Noninfiltrating; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Recurrence; Tomography, X-Ray Computed

2013
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
    Breast cancer research and treatment, 2012, Volume: 132, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome

2012